“FDA Gives Thumbs Up for IV Maintenance Dosing of Leqembi (Lecanemab-Irmb) to Combat Early Alzheimer’s Disease in the US!”
Welcome to the Future of Alzheimer’s Treatment! Exciting News from BioArctic AB (publ) and Eisai STOCKHOLM, Jan. 26, 2025 /PRNewswire/ — BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic’s partner Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi as a once every four…